Our HTDS assays identified several combinations of EGFR+MTOR/AKT pathway inhibitors as effective at inhibiting the growth of EGFR-driven GBM samples, with erlotinib+MLN0128 ranking first (Figure 1e). This evidence concerns the gene MTOR and glioblastoma.